Aprea Therapeutics, Inc.
APRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781983
No open-market purchases or sales by Aprea Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $1.90M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:21 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 16, 2026 | Jan 13, 2025 | Feb 2, 2024 | Mar 30, 2023 | Jan 13, 2022 |
| Operating expenses | $13.5M | $15.8M | $16.1M | $113.4M | $37.4M |
| Research and development | $7.04M | $9.36M | $7.63M | $16.4M | $23.9M |
| Selling, general and administrative | $6.48M | $6.46M | $8.43M | $21.0M | $13.6M |
| Operating income | -$13.2M | -$14.3M | -$15.5M | – | – |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$12.6M | -$13.0M | -$14.3M | -$112.7M | -$37.1M |
| EPS, basic | $-1.93 | $-2.35 | $-3.95 | $-67.99 | $-1.74 |
| EPS, diluted | $-1.93 | $-2.45 | $-3.95 | $-68.16 | $-1.74 |
| Weighted shares, basic | 6.54M | 5.51M | 3.62M | 1.66M | 21.3M |
| Weighted shares, diluted | 6.54M | 5.51M | 3.62M | 1.66M | 21.3M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022! | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 16, 2026 | Jan 13, 2025 | Feb 2, 2024 | Mar 30, 2023 | Jan 13, 2022 |
| Cash and equivalents | $14.6M | $22.8M | $21.6M | $28.8M | $53.1M |
| Total current assets | $15.6M | $23.6M | $22.5M | $30.2M | $56.6M |
| Property, plant and equipment | $59.8K | $81.5K | $88.4K | $2.32K | $23.9K |
| Total assets | $15.9M | $24.0M | $22.7M | $30.2M | $56.8M |
| Accounts payable | $713.7K | $1.35M | $1.67M | $842.8K | $1.77M |
| Total current liabilities | $2.76M | $3.36M | $4.39M | $3.20M | $7.32M |
| Total liabilities | – | – | – | $3.20M | $7.32M |
| Shareholders' equity | $12.4M | $19.3M | $17.0M | $25.6M | $49.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 16, 2026 | Jan 13, 2025 | Feb 2, 2024 | Mar 30, 2023 | Jan 13, 2022 |
| Operating cash flow | -$12.9M | -$13.6M | -$12.2M | -$25.0M | -$37.7M |
| Capital expenditures | – | $15.5K | $93.1K | – | – |
| Free cash flow | – | -$13.6M | -$12.3M | – | – |
| Depreciation and amortization | $21.7K | $22.3K | $7.05K | $4.40K | $12.8K |
| Investing cash flow | – | -$15.5K | -$93.1K | – | – |
| Financing cash flow | $4.64M | $14.8M | $5.14M | $683.0K | $1.75M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 4, 2026 | 14.2M | +124.9% | SEC |
| Aug 12, 2026 | 12.6M | +116.1% | SEC |
| May 13, 2026 | 12.4M | +123.9% | SEC |
| Mar 16, 2026 | 11.5M | +108.5% | SEC |
| Nov 11, 2025 | 6.31M | +16.1% | SEC |
| Aug 11, 2025 | 5.83M | +7.2% | SEC |
| May 13, 2025 | 5.53M | +1.9% | SEC |
| Mar 25, 2025 | 5.49M | +1.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-20 in Q1 2023.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.